{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:24:28Z","timestamp":1790342668240,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12325-019-01061-x","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T17:02:32Z","timestamp":1566406952000},"page":"2866-2880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey"],"prefix":"10.1007","volume":"36","author":[{"given":"Olivier","family":"Morand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leone","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409816666298","volume":"4","author":"RN Giugliani","year":"2016","unstructured":"Giugliani RN, Niu D-M, Ramaswami U, West M, Hughes D, Kampmann C, Pintos-Morell G, et al. A 15-year perspective of the Fabry outcome survey. J Inborn Errors Metab Screen. 2016;4:1\u201312.","journal-title":"J Inborn Errors Metab Screen."},{"issue":"1","key":"1061_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, Korver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1061_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1061_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;190:130\u20135.","journal-title":"J Pediatr"},{"issue":"1","key":"1061_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166(1):172\u20137.","journal-title":"J Pediatr"},{"issue":"5","key":"1061_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450\u20136.","journal-title":"Circ Cardiovasc Genet."},{"issue":"9813","key":"1061_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379(9813):335\u201341.","journal-title":"Lancet"},{"issue":"1","key":"1061_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"1061_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58(8):548\u201352.","journal-title":"J Hum Genet"},{"key":"1061_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijns3020006","author":"P Schielen","year":"2017","unstructured":"Schielen P, Kemper EA, Gelb MH. Newborn screening for lysosomal storage diseases: a concise review of the literature on screening methods, therapeutic possibilities and regional programs. Int J Neonatal Screen. 2017. \n                    https:\/\/doi.org\/10.3390\/ijns3020006\n                    \n                  .","journal-title":"Int J Neonatal Screen."},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","volume":"10","author":"M Arends","year":"2015","unstructured":"Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77.","journal-title":"Orphanet J Rare Dis."},{"issue":"11","key":"1061_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790\u20136.","journal-title":"Genet Med."},{"issue":"2","key":"1061_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1061_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005;42(3):247\u201352.","journal-title":"J Med Genet."},{"issue":"2","key":"1061_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94(2):153\u20138.","journal-title":"Heart"},{"issue":"21","key":"1061_CR17","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"key":"1061_CR18","first-page":"CD006663","volume":"7","author":"R El Dib","year":"2016","unstructured":"El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;7:CD006663.","journal-title":"Cochrane Database Syst Rev."},{"key":"1061_CR19","unstructured":"Amicus Therapeutics, Inc. FDA Approves Galafold\u2122 (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease. 2018. \n                    http:\/\/ir.amicusrx.com\/news-releases\/news-release-details\/fda-approves-galafoldtm-migalastat-treatment-certain-adult\n                    \n                  . Accessed 21 Nov 2018."},{"key":"1061_CR20","unstructured":"European Medicines Agency. EPAR summary for the public. Galafold (migalastat). 2016. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004059\/WC500208437.pdf\n                    \n                  . Accessed 27 Mar 2018."},{"key":"1061_CR21","unstructured":"Amicus Therapeutics UK Ltd. Galafold\u2122 (migalastat) 123\u00a0mg hard capsules. Summary of Product Characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004059\/WC500208434.pdf\n                    \n                  . Accessed 16 Apr 2018."},{"issue":"19","key":"1061_CR22","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","volume":"27","author":"RWD Welford","year":"2018","unstructured":"Welford RWD, Muhlemann A, Garzotti M, Rickert V, Groenen PMA, Morand O, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018;27(19):3392\u2013403.","journal-title":"Hum Mol Genet"},{"key":"1061_CR23","unstructured":"ClinicalTrials.gov. Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY). ClinicalTrials.gov identifier: NCT03425539. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03425539\n                    \n                  . Accessed 06 Nov 2018."},{"issue":"2","key":"1061_CR24","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129\u201338.","journal-title":"Ann Acad Med Singapore"},{"issue":"7","key":"1061_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cns.12542","volume":"22","author":"JM Politei","year":"2016","unstructured":"Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568\u201376.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"1061_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1155\/2006\/828964","volume":"11","author":"AL Gibas","year":"2006","unstructured":"Gibas AL, Klatt R, Johnson J, Clarke JT, Katz J. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag. 2006;11(3):185\u201392.","journal-title":"Pain Res Manag."},{"issue":"Suppl B","key":"1061_CR27","doi-asserted-by":"publisher","first-page":"11B\u20135B","DOI":"10.1155\/2011\/974573","volume":"25","author":"MI Sanchez","year":"2011","unstructured":"Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):11B\u20135B.","journal-title":"Can J Gastroenterol."},{"issue":"1","key":"1061_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.WON.0000438019.21229.b7","volume":"41","author":"FM Schmidt","year":"2014","unstructured":"Schmidt FM, Santos VL. Prevalence of constipation in the general adult population: an integrative review. J Wound Ostomy Continence Nurs. 2014;41(1):70\u20136.","journal-title":"J Wound Ostomy Continence Nurs."},{"issue":"10","key":"1061_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","volume":"30","author":"N Uceyler","year":"2014","unstructured":"Uceyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in fabry disease. Clin J Pain. 2014;30(10):915\u201320.","journal-title":"Clin J Pain"},{"key":"1061_CR30","unstructured":"Fabry Registry. Annual Report 2013. 2013. \n                    http:\/\/www.fabry.org\/fsig.nsf\/PDFs\/PDFsR\/$File\/2013_Annual_Report.pdf\n                    \n                  . Accessed 8 Mar 2018."},{"key":"1061_CR31","unstructured":"Fabry Outcomes Survey. Annual Report 2016. 2017. \n                    http:\/\/www.fabrynetwork.org\/wp-content\/uploads\/2017\/11\/FOS-Patient-Report-2016-Final.pdf\n                    \n                  . Accessed 8 Mar 2018."},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1186\/s12889-015-2350-9","volume":"15","author":"DC Glass","year":"2015","unstructured":"Glass DC, Kelsall HL, Slegers C, Forbes AB, Loff B, Zion D, et al. A telephone survey of factors affecting willingness to participate in health research surveys. BMC Public Health. 2015;15:1017.","journal-title":"BMC Public Health."},{"issue":"9250","key":"1061_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0140-6736(00)03554-6","volume":"357","author":"FP Peters","year":"2001","unstructured":"Peters FP, Vermeulen A, Kho TL. Anderson-Fabry\u2019s disease: alpha-galactosidase deficiency. Lancet. 2001;357(9250):138\u201340.","journal-title":"Lancet"},{"issue":"4","key":"1061_CR34","doi-asserted-by":"publisher","first-page":"e0193550","DOI":"10.1371\/journal.pone.0193550","volume":"13","author":"L Lavalle","year":"2018","unstructured":"Lavalle L, Thomas AS, Beaton B, Ebrahim H, Reed M, Ramaswami U, et al. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS ONE. 2018;13(4):e0193550.","journal-title":"PLoS ONE"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01061-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01061-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01061-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T23:10:31Z","timestamp":1597878631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01061-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01061-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}